(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges

BACKGROUND: Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Tatiana C., Kapiteijn, Ellen, van Wezel, Tom, Smit, Jan W. A., van der Hoeven, Jacobus J. M., Morreau, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719736/
https://www.ncbi.nlm.nih.gov/pubmed/26786320
http://dx.doi.org/10.1186/s12885-016-2060-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719736/
https://www.ncbi.nlm.nih.gov/pubmed/26786320
http://dx.doi.org/10.1186/s12885-016-2060-4

Ejemplares similares